Thomas G. Martin, MD, Discusses Which Abstracts on BCMA Targeted Therapies He’s Excited to See at ASH 2021

Video

Thomas G. Martin, MD, spoke about the abstracts regarding B-cell maturation antigen–targeted treatments he’s excited to see presented at ASH 2021.

Ahead of the 2021 American Society of Hematology Annual Meeting (ASH), Thomas G. Martin, MD, associate director of the Myeloma Program at the University of California San Francisco, discussed the abstracts about therapies targeting B-cell maturation antigen (BCMA) that will be presented.

Transcript:

There’s also going to be a lot in the B-cell maturation antigen [BCMA] space. We’re going to get updates on BCMA-targeted T-cell engaging therapies. [REGN5458]1 is going to have an update and teclistamab [JNJ-64007957] will have an update.2 In the Regeneron study [of REGN5458], 68 patients [were] treated with 5 prior lines of therapy [and results] are going to show an overall response rate of about 73%. Teclistamab is going to [show] about 60% to 65%. These are single-agent antibody therapies. We’ve never seen these levels of responses as single agents. These are going to be moved up into earlier lines of therapy.

We’re also going to get some updates from some other CAR [T-cell therapy] studies, like bb2121.

Another interesting one is from Andrew Cowan, MD.3 He is going to give an update of their BCMA-directed CAR T-cell therapy together with a γ secretase inhibitor trying to increase expression of BCMA on the cell surface. They’re going to report on 18 patients [of whom] 7 had received prior BCMA-targeted therapy.2 One important question is can you give sequential BCMA-targeted therapies and what will they show. I am excited to see the data and see an overall response rate of 89% and a [median] PFS of about 11 months; we have to see how that splits up between prior BCMA or no prior BCMA therapy. They also had a significant amount of [patients with] cytokine release syndrome, about 95%, which is what we see for CAR T-cell therapy. What stood out for me was they had an ICANS [immune effector cell-associated neurotoxicity syndrome] rate of 66%. I’m curious to see what that’s going to look like and why there’s more neurotoxicity when a γ secretase inhibitor is used, so we look forward to having those discussions.

Reference

1. Zonder J, Richter J, Bumma N, et al. Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Presented at: 63rd American Society of Hematology Annual Meeting; December 11-13, 2021; Atlanta, GA. Accessed December 8, 2021. https://bit.ly/3lLyGWW

2. Moreau P, Usmani S, Garfall A, et al. Updated results from MajesTEC-1: Phase 1/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed/refractory multiple myeloma. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-13, 2021; Atlanta, GA. Accessed December 2, 2021. https://bit.ly/32Om8aB

3. Cowan A, Pont M, Sather B, et al. Safety and efficacy of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myeloma. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-13, 2021; Atlanta, GA. Accessed December 2, 2021. https://bit.ly/3G6iSpy

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content